Department of Chemical & Biomolecular Engineering, Sogang University, #1 Shinsu-dong, Mapo-gu, Seoul 121-742, Republic of Korea.
Cancer Lett. 2013 May 10;332(1):110-9. doi: 10.1016/j.canlet.2013.01.021. Epub 2013 Jan 21.
Metastasized and chemoresistant secondary breast cancer treatment commonly shows very low efficacy. A new efficient treatment method is required to overcome the limitation against the secondary breast cancer. In this study, anoikis-resistant breast cancer cells, MDA-MB-231 and MCF-7 were developed as models of chemoresistant and metastatic breast cancer. Doxorubicin encapsulating human serum albumin nanoparticles (HSA+DOX NPs) were fabricated to confirm the benefits of nanoparticles at the treatment of anoikis-resistant breast cancer cells. The side population (SP) fraction in the anoikis-resistant cancer cells was higher than the parental cells. HSA+DOX NPs were more cytotoxic to anoikis-resistant cancer cells than free doxorubicin. The confocal microscope images demonstrated HSA+DOX NPs to deliver more doxorubicin into cells compared to the free doxorubicin by bypassing the drug efflux pump systems of anoikis-resistant cancer cells. In this study, a nanomedicine-based drug delivery carrier shows a potential in treating a metastasized and chemoresistant breast cancer.
转移性和化疗耐药的乳腺癌治疗通常显示出非常低的疗效。需要一种新的有效治疗方法来克服对继发性乳腺癌的限制。在这项研究中，开发了耐失巢凋亡的乳腺癌细胞 MDA-MB-231 和 MCF-7 作为化疗耐药和转移性乳腺癌的模型。阿霉素包封的人血清白蛋白纳米粒（HSA+DOX NPs）被制备以确认纳米粒在治疗耐失巢凋亡的乳腺癌细胞中的益处。失巢凋亡抗性癌细胞中的侧群（SP）分数高于亲本细胞。与游离阿霉素相比，HSA+DOX NPs 对耐失巢凋亡癌细胞的细胞毒性更强。共聚焦显微镜图像表明，与游离阿霉素相比，HSA+DOX NPs 通过绕过耐失巢凋亡癌细胞的药物外排泵系统，将更多的阿霉素递送到细胞内。在这项研究中，基于纳米医学的药物递送载体显示出在治疗转移性和化疗耐药性乳腺癌方面的潜力。
